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Abstract
Purpose Depression is highly prevalent in advanced cancer
patients, but the diagnosis of depressive disorder in patients
with advanced cancer is difficult. Screening instruments
could facilitate diagnosing depressive disorder in patients
with advanced cancer. The aim of this study was to
determine the validity of the Beck Depression Inventory
(BDI-II) and a single screening question as screening tools
for depressive disorder in advanced cancer patients.
Methods Patients with advanced metastatic disease, visiting
the outpatient palliative care department, were asked to fill
out a self-questionnaire containing the Beck Depression
Inventory (BDI-II) and a single screening question “Are
you feeling depressed?” The mood section of the PRIME-
MD was used as a gold standard.
Results Sixty-one patients with advanced metastatic disease
were eligible to be included in the study. Complete data
were obtained from 46 patients. The area under the curve of
the receiver operating characteristics analysis of the BDI-II
was 0.82. The optimal cut-off point of the BDI-II was 16
with a sensitivity of 90% and a specificity of 69%. The
single screening question showed a sensitivity of 50% and a
specificity of 94%.
Conclusions The BDI-II seems an adequate screening tool
for a depressive disorder in advanced cancer patients. The
sensitivity of a single screening question is poor.
Keywords Depression.Advanced cancer.Validation.
Screening tool.BDI-II
Introduction
Depression seems highly prevalent in patients with ad-
vanced cancer. In different studies, a large variation of
prevalence of depression in advanced cancer (4% to 58%)
is reported [1]. This large variation in prevalence can be
explained by the use of different research samples with
different risk factors like cancer type, age, sex, history of
depression, alcohol abuses, and by the use of different
assessment tools [2–4]. In some patients with advanced
cancer, a depressive disorder as defined in the DSM-IV can
be diagnosed, whereas others experience symptoms of
depression and low mood but do not meet the diagnostic
criteria of the DSM-IV. Both situations are associated with
a lower quality of life and consequently cause a burden for
the patient and his caregivers [5, 6].
In patients with advanced cancer, several factors can
influence the diagnostic process of depression. Firstly,
F. Warmenhoven (*): Y. Engels: K. Vissers
Department of Anesthesiology, Pain and Palliative Medicine,
Radboud University Nijmegen Medical Centre,
Huispost 630, P.O. Box 9101, 6500 HB, Nijmegen,
The Netherlands
e-mail: f.warmenhoven@anes.umcn.nl
E. van Rijswijk: C. van Weel
Department of Primary and Community Care,
Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
C. Kan
Department of Psychiatry,
Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
J. Prins
Department of Medical Psychology,
Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
Support Care Cancer (2012) 20:319–324
DOI 10.1007/s00520-010-1082-8specific physical signs and symptoms presented in a patient
with advanced cancer, such as weight loss or fatigue, can
originate from advanced cancer or from depression [7].
Physical symptoms and depressive symptoms may partly
share a common pathway of distress [8], which makes it
difficult to distinguish between cause and effect: physical
symptoms may increase a depressed feeling on the one
hand and on the other hand a depressed feeling may result
in more physical complaints [9, 10]. Secondly, it may be
difficult to distinguish grief from depression in patients
with advanced cancer [11]. Thirdly, for both patient and
physician emotional issues are difficult to address in this
phase of life. Only a minority (17%) of advanced cancer
patients explicitly express their emotional distress to their
physician and physicians themselves do not often address
emotional problems in conversations with advanced cancer
patients, possibly because they do not feel well trained in
communication with palliative care patients [12, 13, 17].
The recognition of depression is not optimal for
oncologists [14, 15] and other physicians as well [16]
because of the reasons mentioned. If patients with advanced
cancer who are suffering from a depressive disorder are not
identified, they will not be able to benefit from the
pharmacological and psychological treatments that are
considered beneficial [16, 18, 19].
Screening instruments could facilitate recognizing de-
pressive disorder in this population [20]. Systematic
screening for symptoms like depression fits into the
principles of advanced care planning that is promoted in
patients with advanced cancer or in need of palliative care
[21]. The ideal screening instrument combines a high
sensitivity with a high specificity. When using a cut score
in a screening instrument, the optimal cut score for a
specific patient group can be determined with a receiver
operating characteristics analysis. The usefulness of a
screening tool depends on the positive and negative
predictive value considering the main aim of the screening.
When screening for depression in patients in a palliative
trajectory, given the vulnerability of these patients and the
consequences of depression for their health status and
quality of life, a high negative predictive value seems most
important. False positive cases can be ruled out in further
diagnostic assessment.
Recently, screening for depression with one or two simple
questions was suggested to be highly specific [22], although
different studies report different findings on psychometric
values of short screening methods [23]. A short screening
method is appealing because the costs would be considerably
lower than other methods for diagnosing depressive disorder;
it is time efficient and many people can be screened for
depression in a quick and simple way.
The Beck Depression inventory (BDI-II) is one of the
most widely used screening tools for depression and it may
provide a useful method for screening for depression in
palliative care [24–26]. This inventory is a self-report
questionnaire that was originally developed to rate the
severity of depressive symptoms [27]. The BDI-II has
shown good psychometric qualities as a screening tool for
depression. However, the BDI-II contains several items on
somatic symptoms of depression (for example, questions
about loss of energy, fatigue, and loss of appetite), which
may lead to an overestimation of positive cases in a patient
group with somatic illness. The BDI-II has been validated
in many samples including cancer patients [28].
The aim of the present study was to assess the validity of
the BDI-II and a single screening question as screening
tools for depression in Dutch-speaking patients with
advanced cancer. The hypothesis was that both the BDI-II
and the single screening question are adequate screening
tools for depressive disorders in Dutch advanced cancer
patients.
Methods
Ethical approval and informed consent
The study received approval of the medical ethical
committee of the Radboud University Nijmegen Medical
Centre. After obtaining informed consent, patients were
asked to fill out a self-report questionnaire. Patients who
were unable to read and understand the Dutch language
were excluded from participating in this study.
Sample and design
From December 2003 until March 2007, all consecutive
patients with advanced, non-curable stages of metastatic
cancer referred to a new outpatient palliative care depart-
ment at the Radboud University Nijmegen Medical Centre
were asked to participate in the study by their treating
physician. Patients considered by their physician to be too
ill to participate were not asked.
Questionnaires and data collection
Patients were asked to provide demographic information.
The BDI-II and a single screening question “Are you
feeling depressed?” were used to screen for depression. The
BDI-II is a 21-item self-report questionnaire with four
response options for each item. Items of the BDI-II relate to
different symptoms of depression such as sadness, hope-
lessness, self-blame, guilt, fatigue, and loss of appetite. On
each item, patients are asked to choose the statement that
best describes their attitude towards the item. Scores of the
BDI-II can vary from 0 to 63 and are often classified as
320 Support Care Cancer (2012) 20:319–324follows: 0–13 no depression, 14–19 mild depression, 20–28
moderate depression, and 29–63 severe depression [29].
Patients were asked to fill out the questionnaire during
their visit at the outpatient department or at home. The
mood section of the PRIME-MD [30] was administered as
a gold standard for the clinical diagnosis of a depressive
disorder by the physician, who was blind to the results of
the questionnaire. The PRIME-MD is a structured interview
based on the DSM-IV classification for depressive disorder
and has been validated in oncology patients [31]. The
PRIME-MD provides standardized questions that focus
directly on key diagnostic symptoms and a depressive
disorder was diagnosed when patients fulfilled the DSM-IV
criteria. The time required to complete the PRIME-MD
mood section is approximately 10 min.
Statistical analysis
Statistical analysis was performed with SPSS 16.0. Means,
sensitivity, specificity, and positive and negative predictive
value were computed. A receiver operating characteristics
(ROC) analysis was performed to determine the optimal cut
score for the BDI-II as a screen for depression in this
population.
Results
From December 2003 until March 2007, 61 patients (29
men, 32 women) were eligible to be included in the study.
The inclusion period of this study has been relatively long
because the outpatient department for palliative care
patients was a new facility in the hospital and, consequent-
ly, referral numbers were low. Patients suffered from a
variety of advanced cancers (23% colon carcinoma, 16%
breast cancer, 8% head and neck cancer, 8% lung cancer,
45% some other malignancy). Of the 61 eligible patients,
20 patients (33%) deceased within 6 months. Seven eligible
patients refused to participate in the study.
Among the 54 patients who enrolled in the study,
administration of the PRIME-MD was not completed in eight
patients (Fig. 1). Therefore, complete data were obtained of
46 patients (26 women, 20 men, mean age 60 years, median
age 58 years). The mean BDI-II score of the 46 patients who
participated in the study was 14.7 (SD 9.9).
Ten out of 46 patients (22%) were diagnosed with a
major depressive disorder using the PRIME-MD. The area
under the curve (AUC) of the ROC analysis of the BDI-II
was 0.82 (Fig. 2). Using the traditional cut score of 14, the
BDI-II demonstrated 90% sensitivity and 64% specificity.
The positive and negative predictive values were 45% and
97%, respectively. However, using a higher cut score of 16
retained high sensitivity (90%) while increasing specificity
to 69%. The positive and negative predictive values were
55% and 96%, respectively. The single screening question
demonstrated 50% sensitivity and 94% specificity. The
positive and negative predictive values of the single
screening question were 71% and 87%, respectively
(Table 1).
Discussion
This study shows that the BDI-II is an adequate screening
tool to detect depressive disorder in patients with
advanced cancer. Using a cut-off point of 16, it has
good sensitivity (90%) and acceptable specificity (69%).
The single screening question performed unsatisfactory,
demonstrating only 50% sensitivity and 94% specificity.
Given the consequences of not recognizing a depression
N= 61 eligible patients 
N=54 participation  N=7 refusal 
N=46 complete data 
obtained (single 
screening question, 
BDI-II, PRIME-MD)
N=8 no gold standard 
obtained 
Fig. 1 Inclusion of patients
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out depression in further diagnostic assessment in
patients who screen positive for depression, a high
sensitivity and high negative predictive value of screen-
ing tools are important and a lower specificity and
positive predictive value are accepted.
The results of this study differ somewhat from previous
findings on psychometric properties of the Beck Depression
Inventory in a cancer patient sample. Katz et al. found that
with a cut score of 16 the BDI had a sensitivity of 73% and
specificity of 100% in a sample of 60 ambulatory patients
with a malignancy of the head and neck region and
identified the optimum cut score at 13 with a sensitivity
of 92% and a specificity of 90% [32]. In the present study,
the participants originated from a heterogeneous group of
patients with advanced cancer, whereas Katz et al. used a
more homogeneous group of ambulatory head and neck
cancer patients. Furthermore, Katz et al. used a different
instrument, the Schedule for Affective Disorders and
Schizophrenia, as a gold standard.
A possible shortcoming of the BDI-II as a screening tool
in advanced cancer patients is that the number of identified
cases could be overestimated because of the somatic items
of the questionnaire. The specificity of the BDI-II in
advanced cancer patients might be increased by excluding
the somatic items (e.g., weight loss, loss of appetite, etc.).
The Beck Depression Inventory Short Form (BDI-SF),
consisting of seven items tapping exclusively affective
symptoms, might be more appropriate for this population.
Love et al. performed a study in 227 women with
metastatic breast disease in which the BDI-SF had a
specificity of 63% and a positive predictive value of 0.52
[33]. This needs further study to determine the psychomet-
ric properties in a more heterogeneous patient group.
The sensitivity of the single screening question in this
study appeared 50%, which is almost similar to the reported
sensitivity of 55% in an earlier study in 74 palliative care
patients [34]. Other previous studies, however, report a
much higher sensitivity of a single screening question in
palliative care patients (72–100%) [23, 35]. The low
sensitivity of the single screening question in this study
may point to difficulties regarding the meaning of the
question. The word depression knows different translations
and different interpretations in the Dutch language. The
exact words that have been used might have influenced the
results [36].
This study has some limitations. Firstly, the relatively
small sample size was recruited from the recently started
outpatient department for palliative care. Small sample size
is not unusual in palliative care, in which recruitment is
difficult and dropout rates are high due to deterioration of
health status and death. Secondly, the selection of participants
in this study was performed by the treating physician. The
number of patients that the physicians considered too ill to
participate was not recorded. In general, though, the partici-
pation of patients in research is high, when their “personal”
treating physician invites them for participation, but it might
introduce selection bias if the physician leaves out highly
distressed patients. Given the relatively high scores on the
BDI-II in this sample, severe bias seems unlikely. Thirdly, we
usedthePRIME-MDasagoldstandard.ThePRIME-MDand
other psychiatric interviews are not validated for advanced
cancer patients specifically. However, they have been
validated in cancer patients [31].
This study offers a contribution to the diagnosis and
screening of depressive disorder in advanced cancer
patients. The Beck Depression Inventory offers a method
for brief and sensitive detection of depressive disorder in
this specific group of patients. If used systematically in
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Fig. 2 Receiving operating characteristic beck depression inventory
(BDI-II)
Table 1 Psychometric properties of single screening question and BDI-II
Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%)
Single screening question 50 69 71 87
BDI-II (cut score 14) 90 64 45 97
BDI-II (cut score 16) 90 69 55 96
322 Support Care Cancer (2012) 20:319–324all advanced cancer patients, this screening tool may increase
and improve physician’s evaluations of not only somatic, but
also psychological complaints of their patients.
To our knowledge, this is the first validation study of the
Dutch Beck Depression Inventory and of a single screening
question to screen for depression in a heterogeneous group
of advanced cancer patients. Secondly, it gives a prevalence
of depression in advanced cancer patients, based on a
clinical diagnosis with the PRIME-MD, contrary to
prevalence numbers acquired by questionnaires. In clinical
practice, the screening tool can serve to alert physicians to
the possibility of depressive disorder and hence give
attention to the mental health status of palliative care
patients, if necessary followed by further diagnostic
assessment and appropriate treatment.
Conclusions
The BDI-II seems to be an adequate screening tool for
depressive disorders in Dutch advanced cancer patients
when using a cut score of 16. The single screening question
is less adequate to detect depression in palliative care
patients, considering the low sensitivity.
Diagnosing depression in patients with advanced cancer
remains a challenge. Using a valid screening tool can
facilitate the process of diagnosing depression in this
specific group of patients.
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